Variable | Nevirapine group | Efavirenz group | P value |
---|---|---|---|
nā=ā67 | nā=ā68 | ||
Age, years: | Ā | Ā | Ā |
MeanāĀ±āSDa | 36.3 Ā±9.2 | 34.8 Ā±6.9 | 0.29 |
Gender, number (%): | Ā | Ā | Ā |
Male | 53 (79.1) | 59 (86.8) | 0.24 |
Female | 14 (20.9) | 09 (13.2) | |
BMIb, kg/m2: | Ā | Ā | Ā |
MeanāĀ±āSD | 18.2 Ā±2.7 | 18.4 Ā±2.7 | 0.57 |
Haemoglobin, g/dL: | Ā | Ā | Ā |
MeanāĀ±āSD | 10.0 Ā±1.9 | 10.4 Ā±1.8 | 0.27 |
CD4 count, cells/mm3: | Ā | Ā | Ā |
Median (Range) | 137 (20ā506) | 139 (7ā588) | 0.90 |
log10 viral load/ml: | Ā | Ā | Ā |
Median (Range) | 5.52 (2.60ā6.58) | 5.19 (2.76ā6.76) | 0.43 |
WHO Staging of HIV disease, number (%): | Ā | Ā | Ā |
Stage-3 | 03 (4.5) | 02 (2.9) | 0.64 |
Stage-4 | 64 (95.5) | 66 (97.1) | Ā |
Type of Tuberculosis, number (%): | Ā | Ā | Ā |
PTBc | 16 (23.9) | 19 (27.9) | 0.06 |
EPTBd | 31 (46.3) | 40 (58.8) | |
Disseminated/Miliary TB | 20 (29.8) | 09 (13.3) | |
Category of ATTe, number (%): | Ā | Ā | Ā |
Category I | 52 (77.6) | 55 (80.9) | 0.64 |
Category II | 15 (22.4) | 13 (19.1) | Ā |
ATT-ARTf gap, days: | Ā | Ā | Ā |
Median (Range) | 27 (11ā85) | 26 (04ā93) | 0.92 |